Alzheimer disease update

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 2, 2010, Pages 15-30

  Matthews, Brandy R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

AGE; ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE COURSE; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FEASIBILITY STUDY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; NEUROBIOLOGY; NEUROPATHOLOGY; PSYCHOSOCIAL CARE; RISK FACTOR;

EID: 78650747708     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000368210.41093.4e     Document Type: Article

References (47)

1. Moller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 1998;248(3):111-122.
2. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26:81-104.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297(5580):353- 356.
4. Iqbal K, Alonso Adel C, Chen S, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005;1739(2-3):198-210.
5. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368(9533):387-403.
6. Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(1):63-72.
7. Gatz M, Reynolds CA, Fratiglionin L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63(2):168-174.
8. Bird TD. Genetic aspects of Alzheimer disease. Genet Med 2008;10(4):231-239.
9. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41(10):1088-1093.
10. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278(16):1349-1356.
11. Howard KL, Filley CM. Advances in genetic testing for Alzheimer's disease. Rev Neurol Dis 2009;6(1):26-32.
12. International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet 1994;31(7):555-559.
13. Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: An update. Ann Med 2008;40(8):562-583.
14. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41(10):1094-1099.
15. Wilson RS, Scherr PA, Bienias JL, et al. Socioeconomic characteristics of the community in childhood and cognition in old age. Exp Aging Res 2005;31(4):393-407.
16. Craft S. Insulin resistance syndrome and Alzheimer disease: Pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006;20(4):298-301.
17. Decarli C. Vascular factors in dementia: An overview. J Neurol Sci 2004;226(1-2):19-23.
18. Roe C, Xiong C, Miller J, Morris J. Education and Alzheimer disease without dementia: Support for the cognitive reserve hypothesis. Neurology 2007;68(3):223-228.
19. Deng J, Zhou DH, Li J, et al. A 2-year follow-up study of alcohol consumption and risk of dementia. Clin Neurol Neurosurg 2006;108(4):378-383.
20. Laitinen MH, Ngandu T, Rovio S, et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: A population-based study. Dement Geriatr Cogn Disord 2006;22(1):99-107.
21. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144(2):73-81.
22. Sitzer DI, Twamley EW, Jeste DV. Cognitive training in Alzheimer's disease: A meta-analysis of the literature. Acta Psychiatr Scand 2006;114(2):75-90.
23. Wang HX, Karp A, Herlitz A, et al. Personality and lifestyle in relation to dementia incidence. Neurology 2009;72(3):253-259.
24. Potter GG, Steffens DC. Contribution of depression to cognitive impairment and dementia in older adults. Neurologist 2007;13(3):105-117.
25. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306-319.
26. Zakzanis KK, Graham SJ, Campbell Z. A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: A neuroimaging profile. Neuropsychol Rev 2003;13(1):1-18.
27. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351(1):56-67.
28. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-198.
29. Kokmen E, Smith GE, Petersen RC, et al. The short test of mental status: Correlations with standardized psychometric testing. Arch Neurol 1991;48(7):725-728.
30. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord 2006;20(4):210-216.
31. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143-1153.
32. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316(5825):750-754.
33. Hampel H, Bürger K, Teiple SK, et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008;4(1):38-48.
34. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15(4):869-877, xi-xii.
35. Wallin AK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for Alzheimer's disease: Levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 2006;21(3):131-138.
36. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65(4):403-413.
37. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluidβ-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66(3):382-389.
38. Britschgi M, Wyss-Coray T. Blood protein signature for early diagnosis of Alzheimer disease. Arch Neurol 2009;66(2):161-165.
39. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
40. Doody RS, Stevens JC, Beck C, et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1154-1166.
41. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: A meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24(1):20-27.
42. Alexopoulos GS, Jeste DV, Chung H, et al. The expert consensus guideline series: Treatment of dementia and its behavioral disturbances. Introduction: Methods, commentary, and summary. Postgrad Med 2005;spec no:6-22.
43. Caselli RJ, Beach TG, Yaari R, Reiman EM. Alzheimer's disease a century later. J Clin Psychiatry 2006;67(11):1784-1800.
44. Dubinsky RM, Stein AC, Lyons K. Practice parameter: Risk of driving and Alzheimer's disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54(12): 2205-2211.
45. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009;7:7.
46. Löppönen M, RäihäI, Isoaho R, et al. Diagnosing cognitive impairment and dementia in primary health care-a more active approach is needed. Age Ageing 2003;32(6):606-612.
47. Sabbagh MN. Drug development for Alzheimer's disease: Where are we now and where are we headed? Am J Geriatr Pharmacother 2009;7(3):167-185.